<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36747013</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>In silico analysis of TUBA4A mutations in Amyotrophic Lateral Sclerosis to define mechanisms of microtubule disintegration.</ArticleTitle><Pagination><StartPage>2096</StartPage><MedlinePgn>2096</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2096</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-28381-x</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an inexorably progressive and degenerative disorder of motor neurons with no currently-known cure. Studies to determine the mechanism of neurotoxicity and the impact of ALS-linked mutations (SOD1, FUS, TARDP, C9ORF72, PFN1, TUBA4A and others) have greatly expanded our knowledge of ALS disease mechanisms and have helped to identify potential targets for ALS therapy. Cellular pathologies (e.g., aggregation of mutant forms of SOD1, TDP43, FUS, Ubiqulin2, PFN1, and C9ORF72), mitochondrial dysfunction, neuroinflammation, and oxidative damage are major pathways implicated in ALS. Nevertheless, the selective vulnerability of motor neurons remains unexplained. The importance of tubulins for long-axon infrastructure, and the special morphology and function of motor neurons, underscore the central role of the cytoskeleton. The recent linkage of mutations to the tubulin &#x3b1; chain, TUBA4A, to familial and sporadic cases of ALS provides a new investigative opportunity to shed light on both mechanisms of ALS and the vulnerability of motor neurons. In the current study we investigate TUBA4A, a structural microtubule protein with mutations causal to familial ALS, using molecular-dynamic (MD) modeling of protein structure to predict the effects of each mutation and its overall impact on GTP binding, chain stability, tubulin assembly, and aggregation propensity. These studies predict that each of the reported mutations will cause notable structural changes to the TUBA4A (&#x3b1; chain) tertiary protein structure, adversely affecting its physical properties and functions. Molecular docking and MD simulations indicate certain &#x3b1; chain mutations (e.g. K430N, R215C, and W407X) may cause structural deviations that impair GTP binding, and plausibly prevent or destabilize tubulin polymerization. Furthermore, several mutations (including R320C and K430N) confer a significant increase in predicted aggregation propensity of TUBA4A mutants relative to wild-type. Taken together, these in silico modeling studies predict structural perturbations and disruption of GTP binding, culminating in failure to form a stable tubulin heterocomplex, which may furnish an important pathogenic mechanism to trigger motor neuron degeneration in ALS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ganne</LastName><ForeName>Akshatha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Balasubramaniam</LastName><ForeName>Meenakshisundaram</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Arkansas Veterans Healthcare Service, McClellan Veterans Medical Center, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SiBioLead, LLC, Little Rock, AR, 72207, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayyadevara</LastName><ForeName>Haarika</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Arkansas, Fayetteville, Fayetteville, AR, 72701, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiaei</LastName><ForeName>Lily</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, Los Angeles, CA, 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RockGen Therapeutics, LLC, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shmookler Reis</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Arkansas Veterans Healthcare Service, McClellan Veterans Medical Center, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SiBioLead, LLC, Little Rock, AR, 72207, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varughese</LastName><ForeName>Kottayil I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiaei</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>RockGen Therapeutics, LLC, Little Rock, AR, 72205, USA. MKiaei@UAMS.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. MKiaei@UAMS.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot 611 (BioMed 1, Rm B-306A), Little Rock, AR, 72205, USA. MKiaei@UAMS.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AR068509</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062254</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG012411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>86-01-1</RegistryNumber><NameOfSubstance UI="D006160">Guanosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495738">PFN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051304">Profilins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006160" MajorTopicYN="N">Guanosine Triphosphate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051304" MajorTopicYN="N">Profilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>MK is the founder, president, and CEO of RockGen Therapeutics, LLC. MB is the founder and CEO of SiBioLead, LLC. RJSR is the co-founder and CSO of SiBioLead, LLC. AG, HA, LK, and KI have no known conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36747013</ArticleId><ArticleId IdType="pmc">PMC9902468</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-28381-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-28381-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tischfield MA, Cederquist GY, Gupta ML, Jr, Engle EC. Phenotypic spectrum of the tubulin-related disorders and functional implications of disease-causing mutations. Curr. Opin. Genet. Dev. 2011;21:286&#x2013;294. doi: 10.1016/j.gde.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2011.01.003</ArticleId><ArticleId IdType="pmc">PMC3100401</ArticleId><ArticleId IdType="pubmed">21292473</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat. Rev. Neurol. 2017;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J. Med. Genet. 2012;49:258&#x2013;263. doi: 10.1136/jmedgenet-2011-100699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84:324&#x2013;331. doi: 10.1016/j.neuron.2014.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.09.027</ArticleId><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensato V, et al. TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations. J. Neurol. 2015;262:1376&#x2013;1378. doi: 10.1007/s00415-015-7739-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7739-y</ArticleId><ArticleId IdType="pmc">PMC6614739</ArticleId><ArticleId IdType="pubmed">25893256</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, van Blitterswijk M. Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS. Neuron. 2014;84:241&#x2013;243. doi: 10.1016/j.neuron.2014.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.002</ArticleId><ArticleId IdType="pubmed">25374348</ArticleId></ArticleIdList></Reference><Reference><Citation>Curiel J, et al. TUBB4A mutations result in specific neuronal and oligodendrocytic defects that closely match clinically distinct phenotypes. Hum. Mol. Genet. 2017;26:4506&#x2013;4518. doi: 10.1093/hmg/ddx338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx338</ArticleId><ArticleId IdType="pmc">PMC7462055</ArticleId><ArticleId IdType="pubmed">28973395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahi-Buisson N, et al. The wide spectrum of tubulinopathies: What are the key features for the diagnosis? Brain. 2014;137:1676&#x2013;1700. doi: 10.1093/brain/awu082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu082</ArticleId><ArticleId IdType="pubmed">24860126</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Ondo Y, Shimojima K, Osaka H, Yamamoto T. A novel TUBB4A mutation G96R identified in a patient with hypomyelinating leukodystrophy onset beyond adolescence. Hum. Genome Var. 2017;4:17035. doi: 10.1038/hgv.2017.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hgv.2017.35</ArticleId><ArticleId IdType="pmc">PMC5540734</ArticleId><ArticleId IdType="pubmed">28791129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo L, et al. TUBB5 and its disease-associated mutations influence the terminal differentiation and dendritic spine densities of cerebral cortical neurons. Hum. Mol. Genet. 2014;23:5147&#x2013;5158. doi: 10.1093/hmg/ddu238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu238</ArticleId><ArticleId IdType="pubmed">24833723</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: Re-evaluating the pathogenesis of TUBA4A in ALS. J. Neurol. Neurosurg. Psychiatry. 2018;89:1350&#x2013;1352. doi: 10.1136/jnnp-2017-317560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317560</ArticleId><ArticleId IdType="pubmed">29540513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersheson J, et al. Mutations in the autoregulatory domain of beta-tubulin 4a cause hereditary dystonia. Ann. Neurol. 2013;73:546&#x2013;553. doi: 10.1002/ana.23832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23832</ArticleId><ArticleId IdType="pmc">PMC3698699</ArticleId><ArticleId IdType="pubmed">23424103</ArticleId></ArticleIdList></Reference><Reference><Citation>Keays DA, et al. Mutations in alpha-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans. Cell. 2007;128:45&#x2013;57. doi: 10.1016/j.cell.2006.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.12.017</ArticleId><ArticleId IdType="pmc">PMC1885944</ArticleId><ArticleId IdType="pubmed">17218254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian G, et al. Tubulin subunits exist in an activated conformational state generated and maintained by protein cofactors. J. Cell Biol. 1997;138:821&#x2013;832. doi: 10.1083/jcb.138.4.821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.138.4.821</ArticleId><ArticleId IdType="pmc">PMC2138046</ArticleId><ArticleId IdType="pubmed">9265649</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivanna BD, Mejillano MR, Williams TD, Himes RH. Exchangeable GTP binding site of beta-tubulin: Identification of cysteine 12 as the major site of cross-linking by direct photoaffinity labeling. J. Biol. Chem. 1993;268:127&#x2013;132. doi: 10.1016/S0021-9258(18)54123-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)54123-5</ArticleId><ArticleId IdType="pubmed">8416920</ArticleId></ArticleIdList></Reference><Reference><Citation>Alushin GM, et al. High-resolution microtubule structures reveal the structural transitions in alphabeta-tubulin upon GTP hydrolysis. Cell. 2014;157:1117&#x2013;1129. doi: 10.1016/j.cell.2014.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.053</ArticleId><ArticleId IdType="pmc">PMC4054694</ArticleId><ArticleId IdType="pubmed">24855948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sase S, et al. TUBB4A mutations result in both glial and neuronal degeneration in an H-ABC leukodystrophy mouse model. Elife. 2020 doi: 10.7554/eLife.52986.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.52986</ArticleId><ArticleId IdType="pmc">PMC7255805</ArticleId><ArticleId IdType="pubmed">32463361</ArticleId></ArticleIdList></Reference><Reference><Citation>Roll-Mecak A. Intrinsically disordered tubulin tails: complex tuners of microtubule functions? Semin. Cell Dev. Biol. 2015;37:11&#x2013;19. doi: 10.1016/j.semcdb.2014.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2014.09.026</ArticleId><ArticleId IdType="pmc">PMC7060838</ArticleId><ArticleId IdType="pubmed">25307498</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorov VA, et al. Mechanical properties of tubulin intra- and inter-dimer interfaces and their implications for microtubule dynamic instability. PLoS Comput. Biol. 2019;15:e1007327. doi: 10.1371/journal.pcbi.1007327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1007327</ArticleId><ArticleId IdType="pmc">PMC6742422</ArticleId><ArticleId IdType="pubmed">31469822</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbier P, et al. Role of tau as a microtubule-associated protein: Structural and functional aspects. Front. Aging Neurosci. 2019;11:204. doi: 10.3389/fnagi.2019.00204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00204</ArticleId><ArticleId IdType="pmc">PMC6692637</ArticleId><ArticleId IdType="pubmed">31447664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bommagani S, et al. A novel tetrazole analogue of resveratrol is a potent anticancer agent. Bioorg. Med. Chem. Lett. 2019;29:172&#x2013;178. doi: 10.1016/j.bmcl.2018.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2018.12.006</ArticleId><ArticleId IdType="pmc">PMC6497071</ArticleId><ArticleId IdType="pubmed">30528695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayyadevara S, et al. Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls. Aging Cell. 2016;15:924&#x2013;939. doi: 10.1111/acel.12501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12501</ArticleId><ArticleId IdType="pmc">PMC5013017</ArticleId><ArticleId IdType="pubmed">27448508</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkam D, Feldman EZ, Singh A, Kiaei M. Profilin1 biology and its mutation, actin(g) in disease. Cell Mol. Life Sci. 2017;74:967&#x2013;981. doi: 10.1007/s00018-016-2372-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2372-1</ArticleId><ArticleId IdType="pmc">PMC5311022</ArticleId><ArticleId IdType="pubmed">27669692</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115:201&#x2013;211. doi: 10.1016/S0306-4522(02)00404-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(02)00404-9</ArticleId><ArticleId IdType="pubmed">12401334</ArticleId></ArticleIdList></Reference><Reference><Citation>Horio T, Murata T. The role of dynamic instability in microtubule organization. Front. Plant Sci. 2014;5:511. doi: 10.3389/fpls.2014.00511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpls.2014.00511</ArticleId><ArticleId IdType="pmc">PMC4188131</ArticleId><ArticleId IdType="pubmed">25339962</ArticleId></ArticleIdList></Reference><Reference><Citation>Woehlke G, et al. Microtubule interaction site of the kinesin motor. Cell. 1997;90:207&#x2013;216. doi: 10.1016/s0092-8674(00)80329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)80329-3</ArticleId><ArticleId IdType="pubmed">9244295</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Yang XJ. Tubulin acetylation: Responsible enzymes, biological functions and human diseases. Cell Mol. Life Sci. 2015;72:4237&#x2013;4255. doi: 10.1007/s00018-015-2000-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2000-5</ArticleId><ArticleId IdType="pubmed">26227334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalimuthu AK, et al. Pharmacoinformatics-based investigation of bioactive compounds of Rasam (South Indian recipe) against human cancer. Sci. Rep. 2021;11:21488. doi: 10.1038/s41598-021-01008-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01008-9</ArticleId><ArticleId IdType="pmc">PMC8563928</ArticleId><ArticleId IdType="pubmed">34728718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 2013;27:221&#x2013;234. doi: 10.1007/s10822-013-9644-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-013-9644-8</ArticleId><ArticleId IdType="pubmed">23579614</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard H, Cholleti A, Pearlman D, Sherman W, Loving KA. Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes. PLoS ONE. 2013;8:e82849. doi: 10.1371/journal.pone.0082849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082849</ArticleId><ArticleId IdType="pmc">PMC3858304</ArticleId><ArticleId IdType="pubmed">24340062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K, et al. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins. 2014;82:1646&#x2013;1655. doi: 10.1002/prot.24551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.24551</ArticleId><ArticleId IdType="pmc">PMC5282925</ArticleId><ArticleId IdType="pubmed">24619874</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MJ, Qian Y, Robinson MC, Tirado-Rives J, Jorgensen WL. Development and testing of the OPLS-AA/M force field for RNA. J. Chem. Theory Comput. 2019;15:2734&#x2013;2742. doi: 10.1021/acs.jctc.9b00054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.9b00054</ArticleId><ArticleId IdType="pmc">PMC6585454</ArticleId><ArticleId IdType="pubmed">30807148</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Perez-Sanchez H, Lightstone FC. A comprehensive docking and MM/GBSA rescoring study of ligand recognition upon binding antithrombin. Curr. Top. Med. Chem. 2017;17:1631&#x2013;1639. doi: 10.2174/1568026616666161117112604.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666161117112604</ArticleId><ArticleId IdType="pmc">PMC5403970</ArticleId><ArticleId IdType="pubmed">27852201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamli H, Zaman GS, Shaikh A, Mobarki AA, Rajagopalan P. A combined chemical, computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in acute myeloid leukemia cells. Oncol. Res. 2021 doi: 10.3727/096504021X16281573507558.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096504021X16281573507558</ArticleId><ArticleId IdType="pmc">PMC8790134</ArticleId><ArticleId IdType="pubmed">34353411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad I, Irfan S, Masroor Ali Beg M, Kamli H, Ali S, Begum N, Rajagopalan P. The SMAC mimetic AT-101 exhibits anti-tumor and anti-metastasis activity in lung adenocarcinoma cells by the IAPs caspase-dependent apoptosis and p65-NF&#x199;B cross-talk. Iranian J. Basic Med. Sci. 2021 doi: 10.22038/ijbms.2021.56400.12586.</Citation><ArticleIdList><ArticleId IdType="doi">10.22038/ijbms.2021.56400.12586</ArticleId><ArticleId IdType="pmc">PMC8528260</ArticleId><ArticleId IdType="pubmed">34712428</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>